Actinium Pharmaceuticals Announces FDA Clearance For IND Application To Study Iomab-ACT As Targeted Conditioning Prior To Bone Marrow Transplant In Sickle Cell Disease Patients
Portfolio Pulse from Benzinga Newsdesk
Actinium Pharmaceuticals has received FDA clearance for its IND application to study Iomab-ACT as a targeted conditioning agent before bone marrow transplants in sickle cell disease patients. The company is collaborating with Columbia University to expand access to cellular therapies and inform gene therapy conditioning studies.
July 25, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Actinium Pharmaceuticals received FDA clearance for its IND application to study Iomab-ACT as a targeted conditioning agent before bone marrow transplants in sickle cell disease patients. This collaboration with Columbia University aims to broaden access to cellular therapies and inform gene therapy conditioning studies.
FDA clearance for the IND application is a significant regulatory milestone that can positively impact Actinium Pharmaceuticals' stock. The collaboration with Columbia University further strengthens the company's position in the cellular therapy space, potentially leading to increased investor confidence and stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100